Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

TEBULA Telacebec to Control Buruli Ulcer and Leprosy in Africa (TEBULA)

Coordinator
Fondation Raoul Follereau, France
Runs
1 June 2025 to 31 May 2029
Status
Running
EU funding
€5.8m
Total cost
€6.1m
Partners
15 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101190742

What the project is doing

In the project's own words, from its summary on CORDIS.

Leprosy (Hansen disease) and Buruli ulcer are among the devastating skin neglected tropical diseases (Skin NTDs) prevalent in sub-Saharan Africa that cause progressive and permanent disabilities, exposing the patients and their families to discrimination, social stigma, and economic burden, adding complex challenges to communities already exposed to extreme inequality. Considering the needs of the most affected populations, children and people living in rural remote areas, current treatments are suboptimal in their complexity and length.

Treating leprosy requires multiple drugs administered for 6 to 12 months. Buruli ulcer treatment requires 3 pills daily at different hours for two months, and lesion healing can take up to 12 months. Both treatments are associated with significant side effects (skin discoloration from clofazimine, exacerbating the stigma that leprosy patients face, and potentially fatal hypersensitivity to dapsone). This proposal aims to transform the treatment of Buruli ulcer and leprosy using the novel compound telacebec.

Telacebec has demonstrated profound activity against Mycobacterium ulcerans and Mycobacterium leprae, the causative agents of Buruli ulcer and leprosy, respectively, whose evolutionary biology has rendered them hypersusceptible to killing by telacebec. We propose to conduct two clinical trials with telacebec-based treatment regimens that will cure Buruli ulcer and leprosy with fewer drugs, shorter duration, and fewer side effects than current therapy.

We will perform this work through an integrated, multidisciplinary consortium of experts with broad experience in drug development, therapeutic delivery, community engagement, stakeholder participation, policy implementation, and capacity building to achieve equitable access to a new standard of care for these diseases.

Topics

Who is involved

OrganisationCityCountryRole
Fondation Raoul FollereauParisFranceCoordinator
Instituut Voor Tropische GeneeskundeAntwerpenBelgiumParticipant
Ministere de la santeCotonouBJAssociatedpartner
Ministere De La Sante De L'hygiene Publique Et De La Couverture Maladie UniverselleAbidjanCIParticipant
Centre Pasteur CameroonYaoundeCMParticipant
Instituto De Salud Carlos IiiMadridSpainParticipant
Alert Comprehensive Specialized HospitalAddis AbabaETAssociatedpartner
Armauer Hansen Research InstituteAddis AbabaETParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Sorbonne UniversiteParisFranceParticipant
Kwame Nkrumah University of Science and Technology KumasiKumasiGhanaParticipant
Liverpool School of Tropical MedicineLiverpool 3United KingdomParticipant
London School of Hygiene and Tropical Medicine Royal CharterLondonUnited KingdomParticipant
Board of Governors of the Colorado State University SystemFort CollinsUnited StatesAssociatedpartner
Global Alliance for Tb Drug Development Non Profit OrganisationNew YorkUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI